DiaMedica Therapeutics, Inc.
DiaMedica-Logo
Navigate DiaMedica Therapeutics, Inc.
Home
About Us
Company Overview
Leadership Team
Board of Directors
Clinical Advisory Boards
Science
Our Science
Pipeline
Diseases We Target
Overview
IgA Nephropathy
African Americans - Hypertensive with CKD
Acute Ischemic Stroke
Investors & Media
Investors Home
Press Releases
Events & Presentations
Nasdaq Stock Information
Analyst Coverage
Financial Reports
Governance
Investor Resources
Careers
Contact
Home
News
News
All News
By Year:
2020
2019
2018
2017
2016
Nov 12, 2018
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
Nov 6, 2018
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
Sep 27, 2018
DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
Sep 5, 2018
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
May 3, 2018
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
Apr 5, 2018
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
Apr 4, 2018
DiaMedica to Present at the MicroCap Conference on April 10th in New York City at the Essex House
Mar 29, 2018
DiaMedica Therapeutics Announces Final Closing of Private Placement
Mar 20, 2018
DiaMedica Therapeutics Announces Closing of Private Placement
Feb 22, 2018
DiaMedica Announces First Enrollment in its PHASE 2 “REMEDY” TRIAL for Acute Ischemic Stroke
« Previous
1
2
3
4
5
6
7
8
Next »